An interventional study of Anti-Aging Compound Capsules in Eye Fatigue, sponsored by China Medical University Hospital. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-18.
Sponsored by China Medical University Hospital · Not applicable, Interventional, and Supportive care
This study aims to evaluate the eye care benefits of anti-aging compound capsules in healthy adults. Participants will consume anti-aging compound capsules containing botanical extracts, omega-3 fatty acids, vitamins, minerals, and hyaluronic acid for four weeks.
The primary outcome is the improvement of ocular discomfort and eye fatigue symptoms assessed using the Ocular Surface Disease Index (OSDI). Secondary outcomes include visual acuity, accommodative function, tear film stability, macular pigment optical density, intraocular pressure, and photostress recovery time. The study will investigate whether daily supplementation with anti-aging compound capsules can improve visual comfort and support ocular health.
Visual fatigue and ocular discomfort have become increasingly prevalent due to prolonged use of digital devices, environmental stressors, and age-related changes in visual function. Nutritional supplementation containing antioxidants, carotenoids, omega-3 fatty acids, vitamins, minerals, and other bioactive compounds may help maintain ocular health and visual performance.
This prospective, single-arm, open-label clinical study aims to evaluate the eye care benefits of anti-aging compound capsules in healthy adults. Twenty-five participants will be enrolled and instructed to consume anti-aging compound capsules for four consecutive weeks.
Each capsule contains 550 mg of a proprietary formulation consisting of grape skin extract, marigold flower extract, red algae extract, fish oil, black soybean seed coat extract, Streptococcus fermentation products containing sodium hyaluronate, black pepper extract, zinc glycinate, selenium yeast, vitamins A, B1, B2, B6, B12, niacin, vitamin E, soybean lecithin, and glycerol fatty acid esters.
Participants will consume two capsules twice daily for a total daily intake of 2,200 mg. Ophthalmic assessments will be performed at baseline, Week 2, and Week 4.
The primary outcome measure is the Ocular Surface Disease Index (OSDI) score. Secondary outcome measures include distance visual acuity, near visual acuity, accommodative response, accommodative facility, tear film break-up time, macular pigment optical density, intraocular pressure, and photostress recovery time.
The study aims to determine whether supplementation with anti-aging compound capsules can improve eye fatigue symptoms and support ocular health in healthy adults.
67 studies on the registry are indexed under Asthenopia; 10 are open to participants now.
This study's enrollment of 25 is below the median of 56 across 56 interventional studies indexed under Asthenopia.
Browse Asthenopia studies →China Medical University Hospital is the lead sponsor of 479 studies on the registry; 115 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Spherical equivalent refractive error less than 700 diopters of myopia (i.e., \< -7.00 D).
Exclusion Criteria:
History of ocular infection or ocular surgery within the past 3 months. Clinically diagnosed ocular diseases, including but not limited to glaucoma, cataract, age-related macular degeneration, or diabetic retinopathy, or a history of ocular procedures such as cataract surgery, retinal laser therapy, or refractive surgery (e.g., LASIK).
Known or self-reported or allergic reaction to any component of the product, including but not limited to fish oil, soybean-derived products, gelatin (bovine source), yeast, or any other listed ingredients.
Individuals with direct affiliation, supervisory, evaluative, or dependent relationships with the research team, including but not limited to:
Students taught, supervised, or evaluated by members of the research team; Laboratory or research assistants, staff, or collaborators within the same research unit; Interns, part-time workers, or employees under the supervision of the research team.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive anti-aging compound capsules containing botanical extracts, omega-3 fatty acids, vitamins, minerals, and hyaluronic acid for 4 weeks. Participants will take 2 capsules twice daily (total daily dose 2,200 mg).
Dietary Supplement: Anti-Aging Compound Capsules
Participants will consume anti-aging compound capsules twice daily for 4 weeks. Each capsule contains 550 mg of a proprietary formulation consisting of grape skin extract, marigold flower extract, red algae extract, fish oil, black soybean seed coat extract, Streptococcus fermentation products containing sodium hyaluronate, black pepper extract, zinc glycinate, selenium yeast, vitamins A, B1, B2, B6, B12, niacin, vitamin E, soybean lecithin, and glycerol fatty acid esters. Total daily intake is 2,200 mg.
Change in Ocular Surface Disease Index (OSDI) Score
Changes in ocular discomfort and eye fatigue symptoms will be assessed using the Ocular Surface Disease Index (OSDI) questionnaire. The OSDI is a validated 12-item questionnaire used to evaluate symptoms related to ocular surface disease and visual function. Assessments will be performed at baseline, Week 2, and Week 4. A decrease in OSDI score indicates improvement in ocular symptoms.
Time frame: baseline / week2 / week4
Change in Distance Visual Acuity (DVA, logMAR)
Changes in distance visual acuity will be measured using a Snellen chart at 6 meters and converted to logarithm of the minimum angle of resolution (logMAR) for statistical analysis. Assessments will be performed at baseline, Week 2, and Week 4.
Time frame: baseline / week2 / week4
Change in Near Visual Acuity (NVA)
Changes in near visual acuity will be assessed using a Snellen near-vision chart at a distance of 40 cm. Assessments will be performed at baseline, Week 2, and Week 4.
Time frame: baseline / week2 / week4
Change in Accommodative Response
Accommodative response will be measured using a Shin-Nippon NVision-K5001 open-field autorefractor, including accommodative lag and accommodative lead. Measurements will be conducted at baseline, Week 2, and Week 4.
Time frame: baseline / week2 / week4
Change in Accommodative Facility (cycles per minute)
Accommodative facility will be assessed using ±0.50 diopter flipper lenses with standard accommodative targets. Results will be recorded as cycles per minute (CPM). Assessments will be performed at baseline, Week 2, and Week 4.
Time frame: baseline / week2 / week4
Change in Tear Film Break-Up Time (TBUT)
Tear film stability will be evaluated using non-invasive tear break-up time measured by a corneal topography system (Topcon CA-800). Assessments will be conducted at baseline, Week 2, and Week 4.
Time frame: baseline / week2 / week4
Change in Macular Pigment Optical Density (MPOD)
Macular pigment optical density will be measured using a macular pigment optical density analyzer. Assessments will be performed at baseline, Week 2, and Week 4.
Time frame: baseline / week2 / week4
Change in Photostress Recovery Time
Photostress recovery time will be assessed by measuring the time required for visual function to return to baseline following exposure to a standardized bright light stimulus. Assessments will be performed at baseline, Week 2, and Week 4.
Time frame: baseline / week2 / week4
Change in Intraocular Pressure (IOP)
Intraocular pressure will be measured using non-contact tonometry. Measurements will be performed at baseline, Week 2, and Week 4.
Time frame: baseline / week2 / week4
Plan to share: No — Individual participant data (IPD) will not be shared due to ethical and privacy considerations. The dataset includes ophthalmic measurements and health-related questionnaire data that could potentially identify participants. Data may be available upon reasonable request and with approval from the corresponding ethics committee.
No publications or documents are linked to this record.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China Medical University Hospital →